ARICEPT significantly improves cognition, daily living over Reminyl in Alzheimers patients

GENEVA, SWITZERLAND (4 APRIL 2002) - Results from the first head-to-head study comparing ARICEPT (donepezil HCl tablets) and Reminyl (galantamine HBr tablets) demonstrated significantly greater improvements in cognition and activities of daily living (ADLs) in mild to moderate Alzheimer's disease (AD) patients treated with ARICEPT vs. Reminyl. ARICEPT-treated patients showed significant benefit over patients receiving Reminyl as measured by the modified 13-item Alzheimer's Disease Assessment Scale-cognitive subscale (modified ADAS-cog), achieved significant improvements on the Mini-Mental State Examination (MMSE), and had significantly greater improvements in ADLs, as measured by the Disability Assessment for Dementia (DAD) scale total score. The study was primarily designed to evaluate safety and tolerability. The first-ever presentation of these data took place at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) in Geneva, Switzerland.

"By comparing two available Alzheimer's disease medications, physicians now have clinical evidence that will help them prescribe the most appropriate treatment for their patients," said study investigator Roy Jones, MD, Research Institute for the Care of the Elderly, St Martin's Hospital, Bath, United Kingdom. "This three month study is encouraging news for mild to moderate Alzheimer's disease patients currently on ARICEPT, as well as those who have yet to initiate treatment." The 12-week, multinational (United Kingdom, Finland, Norway and Germany), head-to-head, randomized open-label study was designed primarily to evaluate the safety and tolerability of ARICEPT (n= 64) and Reminyl (n= 56) in 120 patients with possible or probable mild to moderate Alzheimer's disease. The study also investigated the effects of both treatments on cognition and ADLs, such as meal preparation and finance and correspondence. Trained raters who were blinded to study medication and trial results admin


Page: 1 2 3 4

Related medicine news :

1. First-of-its-kind study of vascular dementia patients taking ARICEPT presented at AAGP meeting
2. Vascular dementia patients taking ARICEPT show significant treatment benefits in cognition and function
3. ARICEPT better tolerated than Exelon in patients with mild to moderate Alzheimers disease
4. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
5. Gastrointestinal disorders are associated significantly with sleepless nights
6. Landmark survey reveals asthma in children remains significantly out of control in the United States
7. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
8. Elderly cancer patients are significantly under-represented in cancer clinical trials
9. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
10. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
11. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer

Post Your Comments:
(Date:10/9/2015)... PA (PRWEB) , ... October 09, 2015 , ... "As ... of two inventors from Philadelphia, Pa. "They have to wear large diapers or pads. ... solutions." , They developed the TROUSAFE to absorb urine leaking from the tip of ...
(Date:10/9/2015)... Australia (PRWEB) , ... October 09, 2015 , ... ... in an upcoming episode of Innovations with Ed Begley Jr., airing 1st QT ... segment, Innovations will educate audiences on MMJ Phytotech Limited (MMJ) – a global ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... Santa Rosa ... their partnership as MD Anderson prepares to go-live on the Epic platform in March ... for early 2016. Santa Rosa will execute the contract by supporting Scheduling Appointment Conversion ...
(Date:10/9/2015)... ... October 09, 2015 , ... Deadly, record-smashing rainfall has caused ... (CCCF) in Columbia, South Carolina. In response, the Foundation has established a national ... both short and long term. 100% of monies donated will go directly to ...
(Date:10/9/2015)... , ... October 09, 2015 , ... Most people assume ... with more vegetables and less meat. While noted T’ai Chi Master and integrative medicine ... and Yang” relationship between the two cuisines and that they potentially complement one another, ...
Breaking Medicine News(10 mins):
(Date:10/9/2015)... -- Eli Lilly and Company (NYSE: LLY ) today ... new jobs to its research and development presence at the ... York . --> ... a translational immuno-oncology hub and a Lilly "portal," which will ... cutting-edge drug discovery capabilities, including chemistry and lead optimization expertise. ...
(Date:10/9/2015)... , Schweiz, October 9, 2015 Der ... Dr.   Yutaka Kondo und Dr.   Junko Takita ...   2015 " geht an Dr.   Yutaka ... Der " JCA-Mauvernay Award   2015 ... Dr.   Junko Takita    ™ , das ...
(Date:10/8/2015)... HERTFORDSHIRE, England and PITTSBURGH ... MYL ), a leading global pharmaceutical company, will host ... th at 5:00 pm ET to review the ... plc (NYSE: PRGO ; TASE) through Mylan,s offer ... review a comprehensive presentation which outlines the compelling proposition ...
Breaking Medicine Technology:
Cached News: